A quiet but revolutionary new national health policy goes into effect this week, ushering in changes that could lead to important medical discoveries that benefit most Americans. There’s just one problem. Implementing the change will require that our country’s health researchers make some fundamental changes in how they do business.
The exclusions of some sections of society from clinical trials is not merely a matter of justice (fair access to research opportunities) it can seriously limit the usefulness of the research and conceal problems with the treatment. As populations in the global north are getting older this limitation becomes more significant. This STAT piece reflects on why the regulatory move by the NIH won’t help.
.
That’s a big group. It currently includes both Donald Trump and Nancy Pelosi, Ruth Bader Ginsberg and Clarence Thomas, as well as the 50 million other older Americans, along with the rest of us who get lucky enough down the road to make it into elderhood.
.